BioCrossroads Adds to Board of Directors

Posted: Updated:
INDIANAPOLIS -

BioCrossroads has announced three new members have joined its board of directors. The additions of Aaron Schacht, J.J. Spegele and Ram Yeleti now gives the board 23 members.

“Aaron, JJ and Ram all represent different sectors within our life sciences community – agbiosciences, clinical research and manufacturing, and healthcare. Their leadership and expertise will provide valuable insight as BioCrossroads continues to advance the strength and opportunities of collaborative and educational initiatives across Indiana’s life sciences and healthcare sectors,” said Darren Carroll, chairman of the BioCrossroads Board of Directors.     

Schacht leads research & development, regulatory affairs and business development at Elanco Animal Health. He is also the Chair of the Board for AgriNovus. Spegele has held leadership roles for clinical research organizations and also was vice president of global business transformation at Quintiles and is currently pursuing a PhD at IU. Yeleti is a clinical leader at Community Health Network's eight hospitals and previously was president of Community Physician Network and president of Community Heart and Vascular. 

  • Perspectives

    • Owe Taxes? What Went Wrong in 2018 and How to Survive It

      The 2018 tax filing deadline came and went. Whew! But for some Americans, the tax headache has just begun. This year was the first filing under the Tax Cuts and Jobs Act and while some taxpayers saw larger refunds others received a rude awakening. If you’re reeling from a large tax burden, this article is for you. The Root of the Problem Remember how excited you were when you received your first paycheck—followed by dismay when you saw how much was taken out for taxes.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Photo of Gary City Hall courtesy of the City of Gary

      McDermott Details Gary Retail Desert

      The city of Gary is facing challenges as it tries to rejuvenate retail business in the city. In an interview with our partners at The Times of Northwest Indiana, Aaron McDermott, president of Latitude Commercial Real Estate Services in Schererville, says the challenge is due to the perception, proximity and demographics associated with Gary. 

    • The Landing project involves redeveloping seven buildings and two parking lots into a mixed-use development.

      New Restaurant Concept Coming to The Landing

      The developers of a $34 million redevelopment project in downtown Fort Wayne have announced a new partnership. Cincinnati-based The Model Group says it is working with Cunningham Restaurant Group to bring a "new and unique" restaurant experience to The Landing.

    • Ball State Among '30 Best Online MBA Degree Programs'

      Ball State University’s Miller College of Business has been recognized as one of The 30 Best Online MBA Degree Programs by MBA Central. The website details 30 programs across the nation and praises Ball State’s program for its variety and affordability.

    • Ryan Wagoner

      Profit With a Purpose: The Rise of Social Impact Investing

      Social impact investing is a fast-growing sector driven by investors who want to use private capital to further the public good. This industry provides a unique opportunity for results-oriented social entrepreneurs to invest in businesses, funds and nonprofits with the intention of generating positive, measurable social change alongside financial return. By engaging in impact investing, investors can align their investment portfolios with their philanthropic priorities.

    • Lilly and Avidity Biosciences Announce Partnership

      Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Avidity Biosciences Inc. have announced a new partnership. The global licensing and research collaboration will work toward the discovery, development and commercialization of new medicines in immunology and other areas.